Bowen Acquisition Corp has a solid equity base from its SPAC structure and a relatively straightforward asset mix dominated by cash and investments. Reported profits have improved thanks to interest income, and there is demonstrated ability to raise capital through equity and, more recently, debt. Looking ahead, the proposed merger with Qianzhi BioTech offers exposure to an innovative niche in ozonated, plant‑based health and wellness products, which aligns with long‑term consumer and regulatory trends toward safer and more natural solutions.

Key risks stem from the fact that Bowen currently has no operating business and no revenue, so all apparent profitability is tied to interest income and will disappear once the SPAC structure changes. Liquidity outside the trust has weakened sharply, with growing short‑term obligations and negative operating cash flow, increasing the pressure to close a deal on time and on budget. For the post‑merger company, additional risks include uncertain intellectual property protection, a lack of publicly available clinical and regulatory data, intense competition in the health and wellness space, and the need to translate a compelling story into consistent commercial performance.

Near‑term outcomes depend heavily on successfully completing and integrating the merger with Shenzhen Qianzhi BioTech while managing limited working capital and new short‑term debt. If the deal closes, the outlook shifts from a financial vehicle to an early‑stage operating company in specialized healthcare and wellness niches, with meaningful upside potential but also significant execution, regulatory, and competitive uncertainty. Until that transition occurs and more detailed operating information is available, the financials mainly reflect a temporary SPAC structure rather than a stable, ongoing business.